Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.

Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.

Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a high risk of relapse. One explanation may be variable adherence to dose-intense chemotherapy. However, little is known about risk factors for delays in therapy and their impact on survival. We conducted an...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Kumar, A, Gimotty, P, Gelfand, J, Buck, G, Rowe, J, Goldstone, A, Fielding, A, Marks, D, Litzow, M, Paietta, E, Lazarus, H, Tallman, M, Luger, S, Loren, A
التنسيق:	Journal article
اللغة:	English
منشور في:	Wiley 2016

مواد مشابهة

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
حسب: Fielding, A, وآخرون
منشور في: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
حسب: Fielding, A, وآخرون
منشور في: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
حسب: Fielding, A, وآخرون
منشور في: (2010)

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
حسب: Sive, J, وآخرون
منشور في: (2012)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
حسب: Fielding, A, وآخرون
منشور في: (2007)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
حسب: Fielding, A, وآخرون
منشور في: (2014)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
حسب: Rowe, J, وآخرون
منشور في: (2008)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
حسب: Ganzel, C, وآخرون
منشور في: (2020)

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
حسب: Fielding, A, وآخرون
منشور في: (2009)

Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study
حسب: Fielding, A, وآخرون
منشور في: (2007)

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
حسب: Goldstone, A, وآخرون
منشور في: (1999)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
حسب: Paietta, E, وآخرون
منشور في: (2008)

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
حسب: Lazarus, H, وآخرون
منشور في: (2006)

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
حسب: Marks, D, وآخرون
منشور في: (2009)

Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993).
حسب: Rowe, J, وآخرون
منشور في: (2003)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
حسب: Rowe, J, وآخرون
منشور في: (2005)

Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.
حسب: Chopra, R, وآخرون
منشور في: (2003)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
حسب: Sive, J, وآخرون
منشور في: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
حسب: Sive, J, وآخرون
منشور في: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
حسب: Sive, J, وآخرون
منشور في: (2010)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
حسب: Mansour, MR, وآخرون
منشور في: (2009)

Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)
حسب: Lazarus, H, وآخرون
منشور في: (2004)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
حسب: Goldstone, A, وآخرون
منشور في: (2001)

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
حسب: Goldstone, A, وآخرون
منشور في: (2008)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
حسب: Moorman, A, وآخرون
منشور في: (2005)

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
حسب: Rowe, J, وآخرون
منشور في: (2001)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
حسب: Moorman, A, وآخرون
منشور في: (2007)

The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years.
حسب: Goldstone, A, وآخرون
منشور في: (2003)

The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study
حسب: Goldstone, A, وآخرون
منشور في: (2004)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups
حسب: Lrrzow, MR, وآخرون
منشور في: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
حسب: Lrrzow, MR, وآخرون
منشور في: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
حسب: Lrrzow, MR, وآخرون
منشور في: (2010)

The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
حسب: Patel, B, وآخرون
منشور في: (2005)

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
حسب: David I. Marks, وآخرون
منشور في: (2013-06-01)

Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol.
حسب: Mansour, MR, وآخرون
منشور في: (2008)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
حسب: Patel, B, وآخرون
منشور في: (2010)

Minimal residual disease is a significant predictor of treatment failure in B lineage adult ALL: final results of the international trial UKALL XII:ECOG 2993
حسب: Patel, B, وآخرون
منشور في: (2009)

Outcome in Philadelphia Chromosome Positive (Ph plus ) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se
حسب: Paietta, E, وآخرون
منشور في: (2008)

Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia: early results from the MRC UKALL12 Study
حسب: Patel, B, وآخرون
منشور في: (2006)

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900
حسب: Hugo F. Fernandez, وآخرون
منشور في: (2019-04-01)